Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mary Ann Gray
AddedMar 31, 2024
UpdatedMay 31, 2026
Mary Ann Gray

Mary Ann Gray

Board Member, Rapt Therapeutics

CrunchbaseLinkedIn

Mary Ann Gray's Career

Rapt Therapeutics
Rapt Therapeutics

South San Francisco, CA, US

Board Member· Board
Keros Therapeutics
Keros Therapeutics

Lexington, MA, US

Board Member· Board
Palisade Bio
Palisade Bio

Carlsbad, CA, US

Board Member· Board
Sarepta Therapeutics
Sarepta Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mary Ann Gray's Career

Rapt Therapeutics
Rapt Therapeutics
Public$440.2M1952015South San Francisco, CA, US
Board Member· Board

Leadership at Rapt Therapeutics

Wendye RobbinsWendye RobbinsBoard Member
Brian WongBrian WongBoard Member
Bill RieflinBill RieflinBoard Member
Linda KozickLinda KozickBoard Member
Dr Michael F GiordanoDr Michael F GiordanoBoard Member
Keros Therapeutics
Keros Therapeutics
Public$230M1052015Lexington, MA, US
Board Member· Board

Leadership at Keros Therapeutics

Jasbir SeehraJasbir SeehraCo-Founder
Carl L. GordonCarl L. GordonBoard Member
Paul YuPaul YuBoard Member
Ran NussbaumRan NussbaumBoard Member
Tomer KarivTomer KarivBoard Member

Similar to Keros Therapeutics

KereosKereosSt. Louis, MO, USImaging Agents, Therapeuticsest. 1999KereosSt. Louis, MO, US · est. 1999

Kereos: A biotech firm innovating molecular imaging agents for cancer and heart disease treatment.

Series B · $27.2M9
Kymera TherapeuticsKymera TherapeuticsWatertown, MA, USDrugsest. 2017Kymera TherapeuticsWatertown, MA, US · est. 2017

Kymera Therapeutics, a global biopharmaceutical firm, innovates drugs for untreatable acute and chronic diseases.

Public · $879M167
Kestrel TherapeuticsKestrel TherapeuticsWayland, MA, USCancer Treatmentest. 2020Kestrel TherapeuticsWayland, MA, US · est. 2020

Kestrel Therapeutics: Pioneering RAS cancer treatment solutions through medical research.

Series A · $40M6
Kezar Life SciencesKezar Life SciencesSouth San Francisco, CA, USMedicines, Therapeuticsest. 2015Kezar Life SciencesSouth San Francisco, CA, US · est. 2015

Kezar Life Sciences, a biotech firm, develops molecular therapeutics for autoimmune disorders in California.

Public · $123M84
Palisade Bio
Palisade Bio
Public$55.4M122001Carlsbad, CA, US
Board Member· Board

Leadership at Palisade Bio

Cristina CsimmaCristina CsimmaBoard Member
John RodenrysJohn RodenrysFounder
Stephanie C. DiazStephanie C. DiazBoard Member
J.D. FinleyJ.D. FinleyCEO
Jim NealJim NealBoard Member

Similar to Palisade Bio

Precision IBDPrecision IBDEncinitas, CA, USTherapeuticsest. 2016Precision IBDEncinitas, CA, US · est. 2016

Precision IBD: A biotech firm specializing in developing precise therapeutics for bowel diseases.

Series A · $13.8M30
Petri BioPetri BioLos Angeles, CA, USTherapeuticsest. 2019Petri BioLos Angeles, CA, US · est. 2019

Petri Bio: A biotech firm innovating gut microbe-based therapeutics.

Seed · $255k3
Bond BiosciencesBond BiosciencesNew York City, NY, USPharmaceuticals, Therapeuticsest. 2016Bond BiosciencesNew York City, NY, US · est. 2016

Bond Biosciences: A private biopharma firm developing non-absorbed oral therapeutics for human diseases.

Series B · $11.8M7
Empire BiotechnologiesEmpire BiotechnologiesSan Francisco, CA, USTherapeuticsest. 2013Empire BiotechnologiesSan Francisco, CA, US · est. 2013

Empire Biotechnologies: Innovating therapies for unmet medical needs, focusing on malabsorption diseases.

Pre-Seed · $1.1M1
Sarepta Therapeutics
Sarepta Therapeutics
Public$1.4B1.2k1980Cambridge, MA, US
Board Member· Board

Leadership at Sarepta Therapeutics

Stephen L. MayoStephen L. MayoBoard Member
Kathy Behrens WilseyKathy Behrens WilseyBoard Member
Marwan FawazMarwan FawazFounder
Doug IngramDoug IngramBoard Member
Hans WigzellHans WigzellBoard Member

Similar to Sarepta Therapeutics

SonoTheraSonoTheraSouth San Francisco, CA, USGenetic Therapiesest. 2021SonoTheraSouth San Francisco, CA, US · est. 2021

SonoThera is a biotechnology company developing ultrasound-mediated nonviral genetic medicines for diseases including Duchenne muscular dystrophy and hemophilia A.

Series B · $185.8M50
Solid BiosciencesSolid BiosciencesCambridge, MA, USGene Therapy, Therapiesest. 2013Solid BiosciencesCambridge, MA, US · est. 2013

Solid Biosciences Inc., a US-based biotech firm, develops therapies and devices for muscular dystrophy.

Public · $441.3M87
PTC TherapeuticsPTC TherapeuticsSouth Plainfield, NJ, USPharmaceuticalsest. 1998PTC TherapeuticsSouth Plainfield, NJ, US · est. 1998

PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.

Public · $1.6B1.4k
Editas MedicineEditas MedicineCambridge, MA, USGene Editing, Therapiesest. 2013Editas MedicineCambridge, MA, US · est. 2013

Editas Medicine, Inc.: A clinical-stage biotech firm pioneering CRISPR-based therapies for rare diseases.

Public · $931.6M226

Mary Ann Gray's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Mary Ann Gray

Mark GrayMark GrayCo-Founder · GrayMetaSmita SircarSmita SircarBoard Member · Gray Matters CapitalErika NorwoodErika NorwoodBoard Member · Gray Matters CapitalMichael T GrayMichael T GrayBoard Member · Gray InsuranceArun GoreArun GoreCEO · Gray Ghost VenturesNathan BocockNathan BocockBoard Member · JackBe